Anakinra has also been used in patients with plaque-type psoriasis and psoriatic arthritis [49] and was the first to be developed in treating other NLRP3­-associated diseases, including cryopyrin-associated periodic syndromes (CAPS), deficiency of IL-1 receptor antagonist (DIRA), and rheumatoid arthritis [64,65]. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.